4 Results for "

B-cell malignancy models

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "B-cell malignancy models" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-150105
CAS No.: 2448172-22-1
Pureté:  98.72%
Synonyms: BMF-219; Menin-MLL inhibitor 21
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-168983
CAS No.: 2952589-57-8
Target:  

Bcl-2 Family

Domaines de recherche:  

Cancer

Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax (HY-15531) in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas .
loading...
    loading...
Cat. No.: HY-P991542
CAS No.: 1931954-95-8

Target:  

CD19

Domaines de recherche:  

Cancer

GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
loading...
    loading...
Cat. No.: HY-P991935

Target:  

Apoptosis

Domaines de recherche:  

Cancer

ANT1034 is humanized anti-CD52 antibody. ANT1034 directs antibody dependent and complement dependent cell cytotoxicity, induces Apoptosis when cross-linked or in the presence of a cross-linking antibody. ANT1034 leads to increased survival in a SCID CD52 tumour xenograft model. ANT1034 can be used for the research of B cell malignancies .
loading...
    loading...